DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic ...( Two timely s...),Health

Two timely sessions at the DIA 45th Annual Meeting reflect the state of today's global biopharmaceutical environment.

Horsham, PA, USA (Vocus) June 5, 2009 -- The Drug Information Association (DIA) 45th Annual Meeting is the biopharmaceutical industry's largest and longest running global, multidisciplinary conference featuring sessions and preconference tutorials on issues affecting drug discovery and development, including two timely sessions reflecting the state of today's global biopharmaceutical environment.

The public policy/law track features a special session on Labeling Risk: Practical Approaches after Wyeth v. Levine (June 22; 1:30 - 3:00 pm).

In March 2009, The Wall Street Journal reported that the Supreme Court ruling in Wyeth v. Levine stated that pharmaceutical companies are not necessarily shielded from failure to warn product liability lawsuits in state courts when the US FDA has determined that approved labeling appropriately explains risk information, This session will explore practical approaches pharmaceutical companies should consider when disseminating risk information to minimize failure to warn liability and to maximize the possibility such liability is preempted.

"We will delve deep into the legal benefits of
'/>"/>